This antibody recognises mouse CD276, otherwise known as B7-H3, a ubiquitously expressed transmembrane glycoprotein and member of the B7 family of co-stimulatory molecules, which acts as both a positive and negative regulator of T-cell-mediated immune responses.CD276 is highly expressed in bone during embryogenesis, and can be induced on dendritic cells and monocytes by inflammatory cytokines. CD276 has been implicated in the development of acute and chronic transplant rejection, and is reported to have therapeutic potential as a regulator of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy. In mice, CD276 has been linked with the development of pathogenic Th2 cells during the induction phase of allergic asthma.
Applications
Flow Cytometry
Recommander des dilutions
Use 10µl of the suggested working dilution to label 1x106 cells in 100µl. The Fc region of monoclonal antibodies may bind non-specifically to cells expressing low affinity Fc receptors. This may be reduced by using SeroBlock FcR (BUF041A or BUF041B).
Protein G affinity chromatography of tissue culture supernatant.
Concentration
Reconstitution dependent.
Forme du produit
Lyophilized
Reconstitution
Reconstitute with 1 ml of distilled water
Formulation
Supplied in Phosphate Buffered Saline with 1% BSA, 5% Sucrose, and 0.09% Sodium Azide.
Stockage
Lyophilized: Store at 4°C. Reconstituted: Store undiluted at 4°C. Do not freeze! This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Notes générales
Rat anti Mouse CD276 antibody, clone MJ8 recognizes mouse CD276, otherwise known as B7-H3, a ubiquitously expressed transmembrane glycoprotein and member of the B7 family of co-stimulatory molecules, which acts as both a positive and negative regulator of T-cell-mediated immune responses.CD276 is highly expressed in bone during embryogenesis, and can be induced on dendritic cells and monocytes by inflammatory cytokines. CD276 has been implicated in the development of acute and chronic transplant rejection, and is reported to have therapeutic potential as a regulator of cell-mediated immune responses to cancer, particularly in conjunction with anti-angiogenic therapy. In mice, CD276 has been linked with the development of pathogenic Th2 cells during the induction phase of allergic asthma (Nagashima et al. 2008).
